UoH partners with Krismo, aims at developing next-generation therapies for inflammatory diseases

As per the partnership, the two institutions will leverage their respective expertise to research and develop innovative therapeutic products targeting a range of inflammatory disorders

Hyderabad: The University of Hyderabad (UoH) and Krismo Biosciences Private Limited, a biotechnology start-up incubated at ASPIRE-BioNEST in UoH, on Saturday announced a partnership aimed at developing next-generation therapies for inflammatory diseases and serious infectious conditions.

As per the partnership, the two institutions will leverage their respective expertise to research and develop innovative therapeutic products targeting a range of inflammatory disorders.

The key focus will also be on the design of antibody-based therapies to effectively combat viral infections, including Dengue, COVID-19, and Influenza, as well as potent toxins produced by harmful bacteria responsible for debilitating conditions like gas gangrene.

UoH School of Life Sciences Department of Animal Biology faculty Prof Nooruddin said the partnership represents the best of both worlds — academic excellence and industry innovation — coming together to address urgent healthcare challenges.

Krismo Biosciences CEO Dr Krishna Mohan expressed his optimism that the collaboration would yield practical, affordable, and impactful solutions for patients.

The initiative was facilitated by the University’s Technology Enabling Centre (UoH-TEC).